ROCKVILLE, Md., Aug. 20, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ: IMAB) (I-Mab or the Company), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer, today announced financial results for the three and six months ended June 30, 2025, and highlighted recent pipeline progress and business updates.
Related Questions
How will the Q2 2025 earnings compare to consensus estimates and affect IMAB's valuation?
What are the key pipeline catalysts and their likelihood of achieving upcoming milestones?
How does IMAB's cash runway and capital allocation plan impact its ability to fund upcoming trials and potential dilution risk?